New Composite Contrast Agents Based on Ln and Graphene Matrix for Multi-Energy Computed Tomography.

The subject of the current research study is aimed at the development of novel types of contrast agents (CAs) for multi-energy computed tomography (CT) based on Ln-graphene composites, which include Ln (Ln = La, Nd, and Gd) nanoparticles with a size of 2-3 nm, acting as key contrasting elements, and graphene nanoflakes (GNFs) acting as the matrix. The synthesis and surface modifications of the GNFs and the properties of the new CAs are presented herein. The samples have had their characteristics determined using X-ray photoelectron spectroscopy, X-Ray diffraction, transmission electron microscopy, thermogravimetric analysis, and Raman spectroscopy.

Hormonal imbalance in two types of endometrial cancer and genetic polymorphism of steroidogenic enzymes.

Objectives: Modern data on endometrial cancer (EC) incidence demonstrate that it is one of the most prevalent gynecologic malignancies. It is possible that some allelic polymorphisms of the genes involved in steroidogenesis or steroid metabolism differently contribute into susceptibility to described types of this disease, namely to type I (which is considered to be hormone dependent) and type II.

Methods: Distribution of allelic polymorphisms of CYP17 (17alpha-hydroxylase/17,20-lyase), CYP19 (aromatase), catechol-O-methyltransferase (COMT) and CYP1B1 (primarily, estrogen 4-hydroxylase) genes was compared totally in 156 endometrial cancer patients, approximately two-third of who belonged (on the basis of case history and some characteristics of host and tumor) to type I of the disease, and one-third to type II.

CYP17 and CYP19 genetic polymorphisms in endometrial cancer: association with intratumoral aromatase activity.

Excessive estrogenic influence is known to be associated with initiation/promotion of endometrial cancer (EC). Allelic polymorphisms of the genes involved in steroidogenesis/steroid metabolism may contribute to EC susceptibility. It is important to know endocrine mechanisms by which such susceptibility is acquired.

Neoadjuvant therapy of endometrial cancer with the aromatase inhibitor letrozole: endocrine and clinical effects.

Objective: To investigate the short-term hormonal and clinical effects of the aromatase inhibitor letrozole (Femara) in patients with endometrial cancer.

Materials And Methods: Ten previously untreated, post-menopausal patients (mean age 59 years) with endometrial cancer, predominantly stage I disease, received letrozole 2.5mg per day for 14 days before surgery.